Form 4: Xenon Pharmaceuticals Director Gillian Cannon Acquires Stock Options

Director Gillian Cannon acquired stock options in Xenon Pharmaceuticals, according to a recent SEC Form 4 filing.

Summary

• Gillian Cannon, a director of Xenon Pharmaceuticals Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of stock options, specifically the right to buy 15,542 common shares.
• These options were granted on June 5, 2024, with an exercise price of $38.16.
• The options vest fully on the earlier of June 4, 2025, or the day before the company's 2025 annual meeting of shareholders.
• Following the transaction, Cannon directly owns 15,542 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects insider confidence, but it's a routine filing.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule suggests a timeline for potential future exercise of the options.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and officers in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant (15,542 shares) would need to be compared against grants to directors at comparable companies (e.g., Biohaven, Neurocrine Biosciences, Sage Therapeutics) to assess its relative significance.
• Vesting schedules are also standard, often tied to continued service or performance milestones.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future prospects.
• The stock options provide an incentive for the director to work towards increasing shareholder value.

Key Dates